Orthotopic model for the analysis of melanoma circulating tumor cells.
Markéta PíckováZuzana KahounováTomasz RadaszkiewiczJiřina ProcházkováRadek FedrMichaela NoskováKatarzyna Anna RadaszkiewiczPetra OvesnáVítězslav BryjaKarel SoučekPublished in: Scientific reports (2024)
Metastatic melanoma, a highly lethal form of skin cancer, presents significant clinical challenges due to limited therapeutic options and high metastatic capacity. Recent studies have demonstrated that cancer dissemination can occur earlier, before the diagnosis of the primary tumor. The progress in understanding the kinetics of cancer dissemination is limited by the lack of animal models that accurately mimic disease progression. We have established a xenograft model of human melanoma that spontaneously metastasizes to lymph nodes and lungs. This model allows precise monitoring of melanoma progression and is suitable for the quantitative and qualitative analysis of circulating tumor cells (CTCs). We have validated a flow cytometry-based protocol for CTCs enumeration and isolation. We could demonstrate that (i) CTCs were detectable in the bloodstream from the fourth week after tumor initiation, coinciding with the lymph node metastases appearance, (ii) excision of the primary tumor accelerated the formation of metastases in lymph nodes and lungs as early as one-week post-surgery, accompanied by the increased numbers of CTCs, and (iii) CTCs change their surface protein signature. In summary, we present a model of human melanoma that can be effectively utilized for future drug efficacy studies.
Keyphrases
- circulating tumor cells
- lymph node
- skin cancer
- circulating tumor
- endothelial cells
- flow cytometry
- papillary thyroid
- neoadjuvant chemotherapy
- sentinel lymph node
- randomized controlled trial
- squamous cell carcinoma
- escherichia coli
- emergency department
- induced pluripotent stem cells
- clinical trial
- atrial fibrillation
- radiation therapy
- acute coronary syndrome
- high resolution
- coronary artery bypass
- pluripotent stem cells
- percutaneous coronary intervention
- case control
- childhood cancer
- multidrug resistant